JP2022550243A5 - - Google Patents
Info
- Publication number
- JP2022550243A5 JP2022550243A5 JP2022506438A JP2022506438A JP2022550243A5 JP 2022550243 A5 JP2022550243 A5 JP 2022550243A5 JP 2022506438 A JP2022506438 A JP 2022506438A JP 2022506438 A JP2022506438 A JP 2022506438A JP 2022550243 A5 JP2022550243 A5 JP 2022550243A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- cdr
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910939944.8 | 2019-09-30 | ||
| CN201910939944 | 2019-09-30 | ||
| PCT/CN2020/116417 WO2021063201A1 (zh) | 2019-09-30 | 2020-09-21 | 抗pd-1抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550243A JP2022550243A (ja) | 2022-12-01 |
| JP2022550243A5 true JP2022550243A5 (enExample) | 2023-09-20 |
Family
ID=75337572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506438A Pending JP2022550243A (ja) | 2019-09-30 | 2020-09-21 | 抗ｐｄ－１抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240425593A1 (enExample) |
| EP (1) | EP4039704A4 (enExample) |
| JP (1) | JP2022550243A (enExample) |
| KR (1) | KR20220070201A (enExample) |
| CN (1) | CN114206931B (enExample) |
| WO (1) | WO2021063201A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024536881A (ja) * | 2021-09-29 | 2024-10-08 | 中山康方生物医▲藥▼有限公司 | 抗ｌａｇ３抗体、医薬組成物、及び使用 |
| CN114835810B (zh) * | 2022-03-31 | 2024-01-05 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体及其应用 |
| WO2023198115A1 (en) * | 2022-04-14 | 2023-10-19 | Beigene Switzerland Gmbh | Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof |
| CN115785269B (zh) * | 2022-11-01 | 2023-09-22 | 四川大学 | 抗pd-l1的抗体及其应用 |
| CN116854820B (zh) * | 2023-06-26 | 2024-02-06 | 华中科技大学同济医学院附属协和医院 | Pd-1非阻断性清除抗体及其用途 |
| CN119798436A (zh) * | 2023-10-10 | 2025-04-11 | 长春金赛药业有限责任公司 | 抗pd-1单克隆抗体及其应用 |
| CN120081943A (zh) * | 2024-04-16 | 2025-06-03 | 赛业（苏州）生物科技有限公司 | 一种人源化pd-l1抗体及其应用 |
| WO2026041144A1 (zh) * | 2024-08-23 | 2026-02-26 | 百图生科(苏州)智能科技有限公司 | Pd-1激动性抗体及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| USPP4816P (en) | 1980-09-11 | 1982-01-26 | Mikkelsens Inc. | Kalanchoe plant |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| CA2942546C (en) | 2014-03-17 | 2022-11-22 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| BR112017001385B1 (pt) * | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| EP3218409A2 (en) * | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| CN105061597B (zh) * | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| MX383464B (es) * | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| HUE068868T2 (hu) * | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| US10981991B2 (en) * | 2015-09-29 | 2021-04-20 | Shanghai Zhangjiang Biotechnology Co., Ltd. | PD-1 antibodies and uses thereof |
| CN107286242B (zh) * | 2016-04-01 | 2019-03-22 | 中山康方生物医药有限公司 | 抗pd-1的单克隆抗体 |
| CN106046162B (zh) * | 2016-06-21 | 2019-04-02 | 大庆东竺明生物技术有限公司 | 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用 |
| CN114456269A (zh) * | 2016-09-21 | 2022-05-10 | 基石药业（苏州）有限公司 | 一种新的pd-1单克隆抗体 |
| CN106519034B (zh) * | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | 抗pd-1抗体及其用途 |
| RU2768404C2 (ru) * | 2016-12-23 | 2022-03-24 | Ремд Биотерапьютикс, Инк. | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) |
| CN110799546B (zh) * | 2017-09-01 | 2023-01-24 | 四川科伦博泰生物医药股份有限公司 | 重组双特异性抗体 |
| JP2021502100A (ja) * | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| CN109467603B (zh) * | 2017-11-14 | 2020-02-21 | 拜西欧斯（北京）生物技术有限公司 | 抗pd-1抗体及其制备方法和应用 |
| US11655295B2 (en) | 2018-01-18 | 2023-05-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-LAG-3 antibody and use thereof |
| EP3768724A4 (en) * | 2018-03-20 | 2022-04-13 | Wuxi Biologics Ireland Limited. | NEW ANTI-PD-1 ANTIBODIES |
| AU2019258468B2 (en) | 2018-04-24 | 2023-06-29 | Ampsource Biopharma Shanghai Inc. | Antibody against TIM-3 and application thereof |
-
2020
- 2020-09-21 WO PCT/CN2020/116417 patent/WO2021063201A1/zh not_active Ceased
- 2020-09-21 JP JP2022506438A patent/JP2022550243A/ja active Pending
- 2020-09-21 EP EP20870685.3A patent/EP4039704A4/en not_active Withdrawn
- 2020-09-21 US US17/631,799 patent/US20240425593A1/en not_active Abandoned
- 2020-09-21 CN CN202080055788.XA patent/CN114206931B/zh active Active
- 2020-09-21 KR KR1020227003770A patent/KR20220070201A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550243A5 (enExample) | ||
| JP6908722B2 (ja) | 抗ｐｄ−１抗体及びその使用 | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| US12098210B2 (en) | Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies | |
| JP2022515318A5 (enExample) | ||
| TW201827464A (zh) | 人程序性死亡受體ｐｄ－１的單株抗體及其片段 | |
| JPWO2018117237A1 (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| JP7328324B2 (ja) | Ｔｉｍ－３に対する抗体およびその使用 | |
| CA3187442A1 (en) | Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof | |
| WO2021063201A1 (zh) | 抗pd-1抗体及其用途 | |
| KR20240069787A (ko) | 항체 표적화 baff-r 및 이의 사용 | |
| CA3192256A1 (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
| JP2024540148A5 (enExample) | ||
| JP2022532991A5 (enExample) | ||
| JP2025537692A (ja) | 癌を治療する方法 | |
| WO2023125289A1 (zh) | 抗pd-1抗体及其用途 | |
| JP7811028B2 (ja) | ヒトｃｘｃｌ１６抗体およびその使用 | |
| JP2024508597A5 (enExample) | ||
| CN118076641A (zh) | 抗cd26抗体及其应用 | |
| JP2024540062A5 (enExample) | ||
| TW202146446A (zh) | 一種抗pd-l1和egfr的四價雙特異性抗體 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| CN116199777B (zh) | 抗hNKG2D抗体及其应用 | |
| WO2026078659A1 (en) | Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma |